Yamada T, Okuda Y, Takasugi K, Itoh K, Igari J
Department of Clinical Pathology, Juntendo University School of Medicine, Tokyo, Japan.
Ann Rheum Dis. 2001 Feb;60(2):124-7. doi: 10.1136/ard.60.2.124.
(1) To determine whether serum concentration of serum amyloid A (SAA) protein is influenced by the SAA1 allele in Japanese patients with rheumatoid arthritis (RA) as previously shown in a healthy control group; and (2) to analyse what factors, based on such an allelic bias, influence the relative SAA values of those patients.
SAA and C reactive protein (CRP) concentrations together with SAA1 genotypes were determined in 316 Japanese patients with RA. The relative SAA values were evaluated as an SAA/CRP ratio.
Comparison of the three SAA1 homozygote groups showed that the SAA/CRP ratio was highest in the 1.5/1.5 group (mean 9.0, p<0.01 v the other two homozygote groups) followed by the 1.3/1.3 group (mean 7.2, NS v the 1.1/1.1 group) and the 1.1/1.1 group (mean 4.0). The SAA/CRP ratio was significantly higher in patients receiving corticosteroids regardless of the presence of allele 1.5. No clear differences in the ratio between patients with or without amyloidosis were found.
The SAA1.5 allele and corticosteroid treatment had a positive influence on SAA concentrations in serum. These findings are important when evaluating SAA concentration in inflammatory diseases and when considering the cause or treatment of amyloidosis.
(1)确定血清淀粉样蛋白A(SAA)的血清浓度是否如先前在健康对照组中所显示的那样,受日本类风湿性关节炎(RA)患者中SAA1等位基因的影响;(2)基于这种等位基因偏差,分析哪些因素影响这些患者的相对SAA值。
测定316例日本RA患者的SAA和C反应蛋白(CRP)浓度以及SAA1基因型。相对SAA值评估为SAA/CRP比值。
对三个SAA1纯合子组进行比较显示,SAA/CRP比值在1.5/1.5组中最高(均值9.0,与其他两个纯合子组相比p<0.01),其次是1.3/1.3组(均值7.2,与1.1/1.1组相比无显著性差异)和1.1/1.1组(均值4.0)。无论是否存在1.5等位基因,接受皮质类固醇治疗的患者的SAA/CRP比值显著更高。有或无淀粉样变性的患者之间该比值未发现明显差异。
SAA1.5等位基因和皮质类固醇治疗对血清中SAA浓度有正向影响。这些发现对于评估炎症性疾病中的SAA浓度以及考虑淀粉样变性的病因或治疗时很重要。